Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  General Electric Company    GE

GENERAL ELECTRIC COMPANY

(GE)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

General Electric : GE Healthcare Introduces Serena Bright, Industry's First Contrast-Enhanced Guided Biopsy Solution

10/20/2020 | 09:32am EST

CHICAGO, IL - - GE Healthcare today announced the availability of Serena Bright(TM) in the United States. Serena Bright(TM) is the industry's first contrast-enhanced guided biopsy solution and will help empower clinicians and patients in their fight against breast cancer. Receiving U.S. Food and Drug Administration 510(k) clearance in June, this technology allows clinicians to conduct breast biopsy exams with contrast guidance using the same mammography equipment, in the same room and with the same staff as the screening or diagnostic mammogram.

Typically, for lesions found with contrast-enhanced mammography and not seen on ultrasound, clinicians will use other imaging guidance, such as MRI, for biopsy procedures. Following an abnormal mammogram, it can take several weeks to get an MRI biopsy.[1] As the backlog of cancer screenings caused by COVID-19 persists, delays in diagnosis will likely lead to presentation at more advanced stages and poorer clinical outcomes, with one study pointing to a potential increase of 33,890 excessive cancer deaths in the U.S. alone.[2]

Serena Bright may help decrease these delays, allowing follow-up biopsy procedures to be done in a matter of days, rather than waiting several weeks for MRI biopsy. When compared to MRI-biopsy guided therapy, the potential benefits of Contrast Enhanced Spectral Mammography (CESM) biopsy include shortened procedure time and improved overall patient experience.[3],[4]

"In the current COVID-19 environment and requirements for shorter appointments to allow physical distancing, time has become our most precious asset," said Dr. Anat Kornecki, Breast Imaging Lead, Breast Care Program, St. Joseph's Health Care London and Scientist with Lawson Health Research Institute in London, Ontario. "This new mammography-guided biopsy technique is a gamechanger, and patients tell us it's a very tolerable experience. It provides a familiar setting, familiar technology and a more comfortable option compared to MRI biopsies, which are longer and conducted with patients lying face down. Ultimately, this may help provide women with answers quickly."

Key to this technology's application is GE Healthcare's SenoBright(TM) HD CESM, a diagnostic breast exam with iodine-based contrast that provides high sensitivity for more accurate breast cancer diagnosis.[5] By highlighting areas of unusual blood flow to localize lesions that need to be biopsied, CESM biopsy - Serena Bright(TM) - provides excellent image quality to help improve clinical confidence.

"Now more than ever, it is critical we put the comfort of patients first and get them answers as fast as possible. We are proud to bring Serena Bright to our customers during a time when this type of innovation is needed most," said Agnes Berzsenyi, President and CEO of Women's Health and X-Ray at GE Healthcare. "We hope this technology can help improve breast cancer outcomes for women during this time of uncertainty."

Health systems worldwide are looking to implement the Serena Bright technology in their fight against breast cancer, with Jefferson Health in Philadelphia being the first health care system in the United States to offer this technology in late 2020.

For more information, visit www.gehealthcare.com/products/mammography/serena-bright.

###

About GE Healthcare:

GE Healthcare is the $16.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter and Insights for the latest news, or visit our website www.gehealthcare.com for more information.

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

All news about GENERAL ELECTRIC COMPANY
07:01aGE HEALTHCARE : Expands AI, Digital and Imaging Solutions at #RSNA2020, Helping ..
BU
11/27TIMELINE-Japan's electricity market reforms
RE
11/26GENERAL ELECTRIC : UK Mega Offshore Wind Farm - to Debut GE Haliade-X Technology..
AQ
11/26GENERAL ELECTRIC : GE Healthcare Announces First X-ray AI to Help Assess Endotra..
AQ
11/25U.S. Consumer Spending Rises for Sixth Straight Month -- 3rd Update
DJ
11/25TODAY'S LOGISTICS REPORT : Building Vaccine Supply Chains; Delivery's Uphill Cli..
DJ
11/25GENERAL ELECTRIC : GE Healthcare Announces U.S. FDA approval of macrocyclic MRI ..
AQ
11/24NEWS HIGHLIGHTS : Top Company News of the Day
DJ
11/24NEWS HIGHLIGHTS : Top Company News of the Day
DJ
11/24Industrials Up As Reduced Election Fears Buoy Government Contractors -- Indus..
DJ
More news
Financials (USD)
Sales 2020 79 649 M - -
Net income 2020 3 511 M - -
Net Debt 2020 20 304 M - -
P/E ratio 2020 31,1x
Yield 2020 0,39%
Capitalization 91 103 M 91 103 M -
EV / Sales 2020 1,40x
EV / Sales 2021 1,40x
Nbr of Employees 189 400
Free-Float 74,3%
Chart GENERAL ELECTRIC COMPANY
Duration : Period :
General Electric Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENERAL ELECTRIC COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 9,56 $
Last Close Price 10,40 $
Spread / Highest target 15,4%
Spread / Average Target -8,03%
Spread / Lowest Target -32,7%
EPS Revisions
Managers
NameTitle
H. Lawrence Culp Chairman & Chief Executive Officer
Carolina Dybeck-Happe Chief Financial Officer & Senior Vice President
Victor Abate Chief Technology Officer & Senior Vice President
James S. Tisch Independent Director
Francisco D'Souza Independent Director
Sector and Competitors